These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15876997)

  • 1. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide.
    Mousa SA; Johansen K
    Int Angiol; 2005 Mar; 24(1):40-2. PubMed ID: 15876997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects.
    Mousa SA; Bozarth J; Barrett JS
    J Clin Pharmacol; 2003 Jul; 43(7):727-34. PubMed ID: 12856386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin.
    Mousa SA
    Int Angiol; 2005 Sep; 24(3):278-81. PubMed ID: 16158039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers.
    Depasse F; González de Suso MJ; Lagoutte I; Fontcuberta J; Borrell M; Samama MM
    Thromb Res; 2003 Jan; 109(2-3):109-17. PubMed ID: 12706639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
    Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
    Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term administration of LMWH - pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients.
    Kuczka K; Baum K; Picard-Willems B; Harder S
    Thromb Res; 2009 Nov; 124(5):625-30. PubMed ID: 19625075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
    Siguret V; Pautas E; Février M; Wipff C; Durand-Gasselin B; Laurent M; Andreux JP; d'Urso M; Gaussem P
    Thromb Haemost; 2000 Nov; 84(5):800-4. PubMed ID: 11127859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
    Jeske W; Fareed J
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():41-7. PubMed ID: 15085465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
    Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
    Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor.
    Mousa SA; Mohamed S
    Thromb Haemost; 2004 Sep; 92(3):627-33. PubMed ID: 15351861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.
    Fossler MJ; Barrett JS; Hainer JW; Riddle JG; Ostergaard P; van der Elst E; Sprogel P
    Am J Health Syst Pharm; 2001 Sep; 58(17):1614-21. PubMed ID: 11556655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.
    Altman R; Scazziota A; Rouvier J
    Haemostasis; 1998; 28(5):229-35. PubMed ID: 10420071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
    Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
    Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients.
    Demirkan F; Akarsu M; Sifil A; Tutucu KN
    Nephron; 2002 May; 91(1):162-3. PubMed ID: 12021535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
    Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
    J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe nondiabetic obese patients: effect of hyperinsulinemia.
    Cella G; Vettor R; Sbarai A; Rossi E; Rampin E; Macor C; Mussap M; Plebani M; Luzzatto G; Girolami A
    Semin Thromb Hemost; 1997; 23(2):129-34. PubMed ID: 9200336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans.
    Kaiser B; Glusa E; Hoppensteadt DA; Breddin HK; Amiral J; Fareed J
    Blood Coagul Fibrinolysis; 1998 Sep; 9(6):517-23. PubMed ID: 9819002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
    Hainer JW; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Leathers T; Leese PT
    Thromb Haemost; 2002 May; 87(5):817-23. PubMed ID: 12038783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis.
    Barrett JS; Gibiansky E; Hull RD; Planès A; Pentikis H; Hainer JW; Hua TA; Gastonguay M
    Int J Clin Pharmacol Ther; 2001 Oct; 39(10):431-46. PubMed ID: 11680668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.